Liver Diseases  >>  Byetta (exenatide)  >>  Phase 4
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Byetta (exenatide) / AstraZeneca
NCT01006889: Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease

Completed
4
24
US
Exenatide, Byetta
University of Florida, Amylin Pharmaceuticals, LLC.
Nonalcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus
12/09
02/10
NCT01208649 / 2008-002325-37: Effects of Exenatide (Byetta®) on Liver Function in Patients With Nonalcoholic Steatohepatitis (NASH)

Completed
4
13
Europe
Exenatide
Ruhr University of Bochum
Nonalcoholic Fatty Liver Disease
09/10
09/10

Download Options